Another fantastic young fellow from GustaveRoussy Clara Helal (And Cédric Pobel) reporting utility of ctDNA in urothelial cancer at #ASCO23 . Data mirror those reported by the great Alex Wyatt team from Vancouver Prostate Centre in the poster session

The level of circulating tumor DNA (ctDNA) shed by a patient’s specific tumor informs the accuracy of blood-based CGP test results. Through a tumor fraction algorithm, our scientists developed a method for quantifying ctDNA in each blood sample: bit.ly/42nOIsy #ASCO23

The Man. The Myth.
miahtao.com/collection/papa
Nickname can be changed.

$GRTS Gritstone bio Granite MSS-CRC expanded due to high demand per BTIG. 🧐 overwhelming evidence and support for ctDNA as an end point for trial. PT $20 $BNTX $MRNA $MRK

Which would you prefer? 3 yrs of adjuvant osimertinib ( #ADAURA ) OR refining use of #ctDNA monitoring in resected #EGFR NSCLC pts to determine who stands to benefit most adjuvant TKI? #ASCO23 #LCSM H. Jack West, MD Sandip Patel MD Joshua Reuss

‼️ Quick summary ‼️of our #ASCO23 poster on #ctDNAmonitoring in patients with advanced #NSCLC 👇🏼 Moffitt Cancer Center Moffitt Research Geoff Oxnard MD Merrida Childress, PhD WashU Liquid Biopsy OncoAlert OncLive.com #LatinosInOncology #LatinasinMedicine

Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors.

Most DNA is inside a cell’s nucleus. As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down and their contents, including…

MRD using ctDNA showed clinical implication in resected CCA: sub-group analysis of phase 2 STAMP trial. Great collaborative work with Natera Oncology George Laliotis

AACR Clinical Cancer Research 🚨
📚: Early ctDNA changes of KRAS G12C in Phase 2 trial of adagrasib 🧪 for advanced #KRASG12C mutant #LCSM 🩺. KRASKickers
Max response seen in first ~3 weeks 🕐.
89.7% patients showed >90% ctDNA decrease 📉
84.6% achieved complete clearance by cycle 2 🧪.…

Small achievement🔓

Nice to see slides/illustrations from our✍🏽work for ASCO Daily News being used by world experts during the ctDNA session.

#ASCO23

Great working together to advance our understandings of ctDNA in cancer! Geoff Oxnard MD Christian Rolfo

My mentor Balazs Halmos is fun to party with and work with. It was incredible to investigate the inequities and patterns of ctDNA testing in metastatic NSCLC with this amazing team. Angelica D'Aiello, MD #ASCO23

🚨Thank you #ASCO23 scientific committee for selecting our work to be presented as a poster today ‼️ special thanks to this amazing group of colleagues and scientists involved in this initiative. Excited to see the future of #ctDNA monitoring in clinical trials & practice!

Dr. Charles Swanton shares an insightful fact:

ctDNA Tests for screening have been created with high specificity to avoid false positives

#ASCO23

Excited to be presenting the results of our REZOLVE (ANZGOG-1101) translational sub-study today in the #GynaecologicalCancer poster session at #ASCO2023

If you’re interested in #ctDNA #cfDNA #ascites #TranslationalBiomarkers come check it out!

Best Cat Dad Ever.
miahcombat.com/collection/cat

WATCH: Bruna Pellini, MD from Moffitt Cancer Center discuss how ctDNA can help predict which patients with lung cancer might experience poorer outcomes on maintenance therapy. #ASCO23 #LCSM ow.ly/9o6m50OI2aq

What value does ctDNA have for monitoring pts with resected #EGFR NSCLC? Report JTO & JTO CRR of 278 pts with resected stage I-IIIA EGFR mutant NSCLC (2015-2017) who had longitudinal ddPCR: 24% positive pre-op (42% of IIIA): 76% of those clear after surgery.

jto.org/article/S1556-…

The Seracare ctDNA on #Onso presented by PacBio is available here: downloads.pacbcloud.com/public/onso/20…

Congratulations to Gillian Vandekerkhove for her Gilead Research Scholars Award! Gillian will be using custom new ctDNA characterization tools to dissect the genomics of metastatic bladder cancer and establish clinically-relevant features. #ASCO2023

Dr Riyaz Shah Sanjay Popat Charu Aggarwal, MD, MPH Ben Solomon Roy Herbst Well it so happens we've designed a trial called Oceanic run through Thoracic Oncology Group of Australasia that is looking to omit chemo if no comutations and plasma ctDNA neg. Hopefully we can deescalate chemo for some #ASCO23 #LCSM

Fantastic job today by our Memorial Sloan Kettering Cancer Center fellows discussing 5-year OPRA data, use of ctDNA in anal cancer and the ongoing Janus trial; well done Floris and Janet! Julio Garcia Aguilar would be proud! ASCO #ASCO23

#daughter #family #mothersday #fathersday
ahtaotee.com/collection/par…

“The next big thing” = perfect title for clinical trials session at #ASCRS23 . Feeling excited and inspired in joining field of CRS. Excellent talks on ANCHOR study, immunotherapy in dMMR rectal ca, MRD detection/ctDNA assay, NEO trial, & ADMIRE-CDII study.

Integrating Liquid Biopsies Into Patient Care and Clinical Trial Design Moderated by DrTyler Paul Johnson #ASCO23 #CRCSM
T3N0 MSS, ctDNA testing Y/N?
Poll split 75:25
Panel: Test result => change management, so Y.
Test sensi imp. Kind of test v imp.
🤔Predictive/Prognostic/type